ImmunoPrecise Antibodies Operating Income

ImmunoPrecise Antibodies (IPA) currently reports a operating income of $-12M as of January 2026. That compares with $-14M in the prior-year period — up 14.1% year over year. Use the charts on this page to explore ImmunoPrecise Antibodies's operating income history and peer comparisons.

ImmunoPrecise Antibodies's operating income increased from $-14M to $-12M — a 14.1% year-over-year increase (period ending January 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

ImmunoPrecise Antibodies reported $-12M in operating income as of January 2026. That compares with $-14M in the prior-year period — up 14.1% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current operating income of $-12M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for ImmunoPrecise Antibodies, and consider following IPA for alerts when major investors trade the stock.

ImmunoPrecise Antibodies is classified in the Healthcare sector. On operating income, it currently shows $-12M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing IPA with unrelated industries.